Renal Cell Carcinoma in Kidney Transplant Recipients

Georgetown Transplant Institute

Belen Mora

Ali Salman

## Preamble:

* **Reference Papers:**
  + [Eggers at al. (2019)](https://www.tandfonline.com/doi/full/10.2217/fon-2019-0397)
* **Study Objectives:** *To be written…*
* **Data Source:** *To be written…*
* **Patient Sample:** *To be written…*
* **Statistical Analysis:** *To be written…*
* **Software:** All analyses were performed using the R Statistical Language (Version 4.4.1; R Foundation for Statistical Computing, Vienna, Austria)

## Patient Characteristics Table:

| **Characteristic** | **Overall** N = 108*1* | **Post Transplant** N = 54*1* | **Pre Transplant** N = 54*1* | **p-value***2* |
| --- | --- | --- | --- | --- |
| Gender |  |  |  | 0.048 |
| Female | 25 (23%) | 11 (20%) | 14 (26%) |  |
| Male | 58 (54%) | 35 (65%) | 23 (43%) |  |
| Unknown/Unspecified | 25 (23%) | 8 (15%) | 17 (31%) |  |
| Age at transplant, y | 56 (47, 62) | 50 (40, 59) | 60 (52, 65) | <0.001 |
| Age at RCC, y | 55 (50, 64) | 55 (50, 64) | 56 (50, 63) | 0.9 |
| Donor status |  |  |  | 0.8 |
| Deceased | 75 (69%) | 38 (70%) | 37 (69%) |  |
| Living | 33 (31%) | 16 (30%) | 17 (31%) |  |
| Principal Diagnosis |  |  |  | 0.5 |
| Hypertensive Nephrosclerosis | 32 (30%) | 13 (24%) | 19 (35%) |  |
| Diabetic Nephropathy | 20 (19%) | 12 (22%) | 8 (15%) |  |
| Glomerular Diseases | 16 (15%) | 10 (19%) | 6 (11%) |  |
| Unspecified/Other | 14 (13%) | 5 (9.3%) | 9 (17%) |  |
| Chronic Liver Disease/Hepatorenal Syndrome | 11 (10%) | 4 (7.4%) | 7 (13%) |  |
| Retransplantation/Graft Failure | 5 (4.6%) | 3 (5.6%) | 2 (3.7%) |  |
| Oncologic Indications | 4 (3.7%) | 2 (3.7%) | 2 (3.7%) |  |
| Amyloidosis | 2 (1.9%) | 2 (3.7%) | 0 (0%) |  |
| Other Nephrotoxicity | 2 (1.9%) | 1 (1.9%) | 1 (1.9%) |  |
| Polycystic Kidney Disease | 2 (1.9%) | 2 (3.7%) | 0 (0%) |  |
| *1*n (%); Median (Q1, Q3) | | | | |
| *2*Pearson's Chi-squared test; Wilcoxon rank sum test; Fisher's exact test | | | | |

## Surgery Characteristics Table:

| **Characteristic** | **Overall** N = 108*1* | **Post Transplant** N = 54*1* | **Pre Transplant** N = 54*1* | **p-value***2* |
| --- | --- | --- | --- | --- |
| Therapy |  |  |  | 0.12 |
| Active Surveillance | 5 (4.6%) | 4 (7.4%) | 1 (1.9%) |  |
| Cryoablation | 12 (11%) | 7 (13%) | 5 (9.3%) |  |
| Immunotherapy | 2 (1.9%) | 2 (3.7%) | 0 (0%) |  |
| Nephrectomy | 86 (80%) | 41 (76%) | 45 (83%) |  |
| Unknown/Unspecified | 3 (2.8%) | 0 (0%) | 3 (5.6%) |  |
| Histopathology |  |  |  | 0.2 |
| Benign | 3 (2.8%) | 2 (3.7%) | 1 (1.9%) |  |
| Chromophobe | 4 (3.7%) | 3 (5.6%) | 1 (1.9%) |  |
| Clear Cell | 38 (35%) | 17 (31%) | 21 (39%) |  |
| Cystic | 5 (4.6%) | 0 (0%) | 5 (9.3%) |  |
| Oncocytic/Sarcomatoid | 5 (4.6%) | 4 (7.4%) | 1 (1.9%) |  |
| Papillary | 40 (37%) | 22 (41%) | 18 (33%) |  |
| Unclassified | 3 (2.8%) | 2 (3.7%) | 1 (1.9%) |  |
| Unknown/Unspecified | 10 (9.3%) | 4 (7.4%) | 6 (11%) |  |
| Grading |  |  |  | 0.004 |
| G1 | 15 (14%) | 12 (22%) | 3 (5.6%) |  |
| G2 | 28 (26%) | 18 (33%) | 10 (19%) |  |
| G3 | 11 (10%) | 6 (11%) | 5 (9.3%) |  |
| G4 | 2 (1.9%) | 1 (1.9%) | 1 (1.9%) |  |
| Unknown/Unspecified | 52 (48%) | 17 (31%) | 35 (65%) |  |
| T-staging |  |  |  | 0.072 |
| T1 | 84 (78%) | 40 (74%) | 44 (81%) |  |
| T2 | 6 (5.6%) | 5 (9.3%) | 1 (1.9%) |  |
| T3 | 3 (2.8%) | 3 (5.6%) | 0 (0%) |  |
| T4 | 1 (0.9%) | 1 (1.9%) | 0 (0%) |  |
| Unknown/Unspecified | 14 (13%) | 5 (9.3%) | 9 (17%) |  |
| *1*n (%) | | | | |
| *2*Fisher's exact test | | | | |